4/A//SEC Filing
ORBIMED CAPITAL II LLC 4/A
Accession 0000947871-06-001040
CIK 0000858803other
Filed
Jun 4, 8:00 PM ET
Accepted
Jun 5, 10:27 AM ET
Size
10.5 KB
Accession
0000947871-06-001040
Insider Transaction Report
Form 4/AAmended
ISALY SAMUEL D
Director
Transactions
- Other
Common Stock
2006-05-31$9.79/sh−629,121$6,159,095→ 1,706,137 total(indirect: FN)
ORBIMED CAPITAL GP II LLC
Director
Transactions
- Other
Common Stock
2006-05-31$9.79/sh−629,121$6,159,095→ 1,706,137 total(indirect: FN)
ORBIMED ADVISORS LLC
Director
Transactions
- Other
Common Stock
2006-05-31$9.79/sh−629,121$6,159,095→ 1,706,137 total(indirect: FN)
Footnotes (4)
- [F1]This Form 4 is an amendment of and replaces that Form 4 filed by the same parties on June 2, 2006. The disposition of securities described herein represents a distribution by Caduceus Private Investments II, LP ("Caduceus") and Caduceus Private Investments II (QP), LP ("Caduceus QP") of these securities to the limited partners in Caduceus and Caduceus QP. This distribution thus does not represent a change to the ultimate owners of the securities and may instead be viewed simply as a transfer into the hands of these ultimate owners.
- [F2]As of 5/31/06, Reporting Persons held 1,706,137 shares of Class A common stock, on behalf of other persons who have the right to receive or the power to direct the receipt of dividends from, or proceeds from sale of, such securities. Of this amount, Caduceus, Caduceus QP and UBS Juniper Crossover Fund, LLC ("Juniper") directly hold 1,090,968, 421,981 and 193,188 shares, respectively. OrbiMed Advisors LLC ("Advisors"), pursuant to its authority under its investment advisory contracts with Juniper, may be considered to hold indirectly 193,188 shares of common stock and OrbiMed Capital GP II LLC ("Capital"), pursuant to its authority under its investment advisory contract with Caduceus and Caduceus QP, may be considered to hold indirectly 1,512,949 shares of common stock.
- [F3]Advisors is a registered adviser under the Investment Advisers Act of 1940, as amended, that acts as an investment adviser to certain collective investment funds which hold Shares of the Issuer. Samuel D. Isaly, a natural person, owns controlling interests in Advisors and Capital. Advisors acts as investment adviser to Juniper. Capital acts as general partner to Caduceus and Caduceus QP. Pursuant to certain agreements and relationships, Advisors and Capital have discretionary investment management authority with respect to the assets of Caduceus, Caduceus QP, and Juniper. Such authority includes the power to vote and otherwise dispose of securities purchased by Caduceus, Caduceus QP and Juniper. The Reporting Person may be deemed to be a director of the issuer by virtue of its having nominated a representative, now Jonathan Silverstein, to serve on the issuer's board of directors.
- [F4]The Reporting Persons disclaim beneficial ownership of the these securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purposes.
Documents
Issuer
AVANIR PHARMACEUTICALS
CIK 0000858803
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001281668
Filing Metadata
- Form type
- 4/A
- Filed
- Jun 4, 8:00 PM ET
- Accepted
- Jun 5, 10:27 AM ET
- Size
- 10.5 KB